NCT02487992View on ClinicalTrials.gov

The Study of CIK Plus S-1 and Bevacizumab as Maintenance Treatment for Patients With Advanced Colorectal Cancer

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

1,200

Participants

Timeline

Start Date

July 31, 2015

Primary Completion Date

July 31, 2043

Study Completion Date

July 31, 2045

Conditions
Colorectal Neoplasms
Interventions
BIOLOGICAL

Cytokine-Induced Killer Cells

CIK cells transfected with cytokine genes possess an improved proliferation rate and a higher cytotoxic activity as compared to regular CIK cells.

All Listed Sponsors
lead

The First People's Hospital of Changzhou

OTHER